Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Am J Med. 2005 Oct;118 Suppl 10A:46S-49S.

Changing travel-related global epidemiology of hepatitis A.

Author information

  • Division of Communicable Diseases and Travel Clinic, Institute of Social and Preventive Medicine of the University of Zurich, World Health Organization Collaborating Center for Travelers' Health, Zurich, Switzerland. travclin@ifspm.unizh.ch

Abstract

Hepatitis A is highly endemic in many emerging cultures. Despite the availability of safe and effective vaccines and some improvements in sanitation in developing countries, hepatitis A remains a significant cause of morbidity for nonimmune travelers visiting such destinations. All are at risk, including short-term vacationers or business travelers who stay in deluxe accommodations. This may have considerable implications on public health. Hepatitis A vaccination programs for travelers have not proven to be effective, since many visitors to destinations at risk (e.g., Mexico) fail to consult health professionals prior to departure. Because 50% of the US population has an anticipated lifetime risk for exposure, universal immunization against hepatitis A should be considered.

PMID:
16271541
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk